Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTSGNASDAQ:HRMYNASDAQ:PTCTNASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTSGBrightSpring Health Services$18.18+1.3%$20.00$9.98▼$24.82$3.18B2.21.27 million shs1.40 million shsHRMYHarmony Biosciences$32.53+0.3%$35.61$28.14▼$41.61$1.87B0.82553,252 shs591,049 shsPTCTPTC Therapeutics$48.37+3.8%$51.27$24.00▼$58.38$3.81B0.58791,095 shs1.26 million shsVERAVera Therapeutics$23.59+7.1%$30.30$21.45▼$51.61$1.50B1.17769,130 shs816,471 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTSGBrightSpring Health Services+1.34%-1.57%-1.78%+4.90%+72.00%HRMYHarmony Biosciences+0.34%-2.05%+1.09%-6.60%-0.52%PTCTPTC Therapeutics+3.80%-12.55%-8.51%+5.43%+70.32%VERAVera Therapeutics+7.13%-8.95%-16.97%-44.10%-42.25%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTSGBrightSpring Health Services2.2982 of 5 stars2.53.00.00.01.90.01.9HRMYHarmony Biosciences4.4685 of 5 stars3.51.00.00.03.34.24.4PTCTPTC Therapeutics4.0129 of 5 stars4.31.00.04.43.10.80.0VERAVera Therapeutics3.1115 of 5 stars3.63.00.00.02.84.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTSGBrightSpring Health Services 2.90Moderate Buy$21.6719.18% UpsideHRMYHarmony Biosciences 3.00Buy$53.3363.95% UpsidePTCTPTC Therapeutics 2.53Moderate Buy$63.7731.84% UpsideVERAVera Therapeutics 3.20Buy$64.67174.13% UpsideCurrent Analyst Ratings BreakdownLatest BTSG, PTCT, VERA, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$78.00 ➝ $75.003/18/2025HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $44.003/14/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$72.00 ➝ $78.003/11/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$41.00 ➝ $55.003/7/2025PTCTPTC TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$67.00 ➝ $70.003/7/2025PTCTPTC TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$55.003/4/2025VERAVera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$77.00 ➝ $71.002/28/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$74.00 ➝ $72.002/27/2025HRMYHarmony BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.002/27/2025VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$59.00 ➝ $61.002/25/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTSGBrightSpring Health Services$11.27B0.28$0.36 per share50.87$3.42 per share5.32HRMYHarmony Biosciences$714.73M2.61$2.43 per share13.38$7.97 per share4.08PTCTPTC Therapeutics$806.78M4.73$2.33 per share20.80($10.85) per share-4.46VERAVera TherapeuticsN/AN/AN/AN/A$1.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTSGBrightSpring Health Services-$154.60M-$0.12N/A22.17N/A-0.38%4.16%0.99%5/1/2025 (Estimated)HRMYHarmony Biosciences$128.85M$2.5115.4210.460.4717.98%23.16%14.24%4/29/2025 (Estimated)PTCTPTC Therapeutics-$626.60M-$4.73N/AN/AN/A-50.32%N/A-16.44%4/24/2025 (Estimated)VERAVera Therapeutics-$95.99M-$2.75N/AN/AN/AN/A-50.13%-39.50%5/8/2025 (Estimated)Latest BTSG, PTCT, VERA, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025N/ABTSGBrightSpring Health Services$0.14N/AN/AN/A$2.74 billionN/A4/29/2025N/AHRMYHarmony Biosciences$0.59N/AN/AN/A$184.26 millionN/A4/24/2025N/APTCTPTC Therapeutics$0.85N/AN/AN/A$437.16 millionN/A2/26/2025Q4 2024VERAVera Therapeutics-$0.83-$0.72+$0.11-$0.72N/AN/A2/25/2025Q4 2024HRMYHarmony Biosciences$0.74$0.85+$0.11$0.85$201.25 million$201.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTSGBrightSpring Health ServicesN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTSGBrightSpring Health Services1.631.350.97HRMYHarmony Biosciences0.283.243.20PTCTPTC TherapeuticsN/A2.102.04VERAVera Therapeutics0.1713.7613.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTSGBrightSpring Health ServicesN/AHRMYHarmony Biosciences86.23%PTCTPTC TherapeuticsN/AVERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipBTSGBrightSpring Health ServicesN/AHRMYHarmony Biosciences30.80%PTCTPTC Therapeutics5.50%VERAVera Therapeutics21.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTSGBrightSpring Health Services35,000174.97 millionN/AOptionableHRMYHarmony Biosciences20057.35 million39.47 millionOptionablePTCTPTC Therapeutics1,41078.87 million72.88 millionOptionableVERAVera Therapeutics4063.75 million49.58 millionOptionableBTSG, PTCT, VERA, and HRMY HeadlinesRecent News About These CompaniesVera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgANApril 3 at 8:00 AM | globenewswire.comPrudential Financial Inc. Grows Position in Vera Therapeutics, Inc. (NASDAQ:VERA)April 3 at 3:51 AM | marketbeat.comVera Therapeutics (NASDAQ:VERA) Reaches New 52-Week Low - Here's WhyApril 2 at 4:11 AM | marketbeat.comAmerican Century Companies Inc. Has $18.14 Million Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)April 2 at 3:41 AM | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Gap Down - Should You Sell?April 1 at 1:17 PM | marketbeat.comPictet Asset Management Holding SA Boosts Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)April 1 at 4:32 AM | marketbeat.com69,724 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Bought by Raymond James Financial Inc.March 30, 2025 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Hits New 1-Year Low - Should You Sell?March 27, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), Erasca (ERAS)March 27, 2025 | markets.businessinsider.comEFG Asset Management North America Corp. Acquires 27,192 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)March 26, 2025 | marketbeat.comSwiss National Bank Purchases 15,700 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)March 26, 2025 | marketbeat.comPlatinum Investment Management Ltd. Has $5.06 Million Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)March 20, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Charles Schwab Investment Management Inc.March 20, 2025 | marketbeat.comVictory Capital Management Inc. Increases Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)March 14, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Buy" by AnalystsMarch 12, 2025 | marketbeat.comVera Therapeutics (VERA) Expected to Announce Quarterly Earnings on WednesdayMarch 12, 2025 | marketbeat.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 11, 2025 | globenewswire.comFY2025 Earnings Forecast for VERA Issued By HC WainwrightMarch 8, 2025 | marketbeat.comVera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much?March 7, 2025 | seekingalpha.comCantor Fitzgerald Has Negative View of VERA FY2025 EarningsMarch 7, 2025 | marketbeat.comCandriam S.C.A. Sells 84,993 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)March 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesThese 3 Iconic Brands Just Announced Bigger Dividend PayoutsBy Leo Miller | March 7, 2025View These 3 Iconic Brands Just Announced Bigger Dividend PayoutsWhy Archer Aviation Stock Could Soar After Palantir PartnershipBy Jeffrey Neal Johnson | March 20, 2025View Why Archer Aviation Stock Could Soar After Palantir PartnershipThe 5 Most Oversold Stocks on the Market Are… By Thomas Hughes | March 28, 2025View The 5 Most Oversold Stocks on the Market Are… The 3 Most Talked About Investments on WallStreetBets Right NowBy Leo Miller | April 2, 2025View The 3 Most Talked About Investments on WallStreetBets Right NowTop 3 Beverage Stocks Pouring Out ProfitsBy Nathan Reiff | March 27, 2025View Top 3 Beverage Stocks Pouring Out ProfitsBTSG, PTCT, VERA, and HRMY Company DescriptionsBrightSpring Health Services NASDAQ:BTSG$18.18 +0.24 (+1.34%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$18.01 -0.17 (-0.94%) As of 07:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BrightSpring Health Services, Inc. operates a home and community-based healthcare services platform in the United States. The company's platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It serves patients through clinical providers and pharmacists. The company was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. BrightSpring Health Services, Inc. was founded in 1974 and is headquartered in Louisville, Kentucky.Harmony Biosciences NASDAQ:HRMY$32.53 +0.11 (+0.34%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$32.45 -0.08 (-0.25%) As of 08:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.PTC Therapeutics NASDAQ:PTCT$48.37 +1.77 (+3.80%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$46.50 -1.87 (-3.87%) As of 08:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Vera Therapeutics NASDAQ:VERA$23.59 +1.57 (+7.13%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$23.05 -0.54 (-2.29%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Reasons Why Halliburton is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
